Bulletin
Investor Alert

New York Markets After Hours

press release

March 9, 2021, 7:01 a.m. EST

NeuBase Therapeutics to Present at Upcoming Investor Conferences in March 2021

PITTSBURGH, March 09, Mar 09, 2021 (GLOBE NEWSWIRE via COMTEX) -- PITTSBURGH, March 09, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. /zigman2/quotes/206101919/composite NBSE -2.72% ("NeuBase" or the "Company"), a biotechnology company accelerating the genetic revolution using a new class of synthetic medicines, announced today that Dietrich A. Stephan, Ph.D., Chief Executive Officer of NeuBase, will present a corporate overview at the H.C. Wainwright Global Life Sciences Conference and at the Oppenheimer 31 [st] Annual Healthcare Conference. Both virtual investor conferences take place in March 2021.

Conference Details:
Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9 [th]
Time: 7:00 a.m. ET
Location: Webcast Link - or at the company's website ( click here )
Event: Oppenheimer 31 [st] Annual Healthcare Conference
Date: Wednesday, March 17 [th]
Time: 11:20 a.m. ET
Location: Webcast Link - or at the company's website ( click here )

The webcasts from both conferences will also be archived on the NeuBase website, www.neubasetherapeutics.com .

About NeuBase Therapeutics
NeuBase is accelerating the genetic revolution using a new class of synthetic medicines which have been shown to be able to increase, decrease and change gene function, as appropriate, to resolve causal genetic defects in living systems. NeuBase's designer PATrOL(TM) therapies are centered around its proprietary drug scaffold to address genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com .

NeuBase Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors, LLC
Daniel@lifesciadvisors.com
OP: (617) 430-7576

NeuBase Media Contact:
Cait Williamson, Ph.D.
LifeSci Public Relations
cait@lifescipublicrelations.com
OP: (646) 751-4366

COMTEX_382395091/2471/2021-03-09T07:00:48

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

/zigman2/quotes/206101919/composite
US : U.S.: Nasdaq
$ 3.93
-0.11 -2.72%
Volume: 100,159
Oct. 25, 2021 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$132.18 million
Rev. per Employee
N/A
loading...

Partner Center

Link to MarketWatch's Slice.